Autopsy report · NCT03947255

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

“Study stopped early due to low patient accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 3 years before it stopped.
• 12 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Seagen Inc.

Sponsor type

Industry

Conditions

Hodgkin Lymphoma; Peripheral T Cell Lymphoma; Anaplastic Large Cell Lymphoma

Interventions

brentuximab vedotin

Participants

12

Sites

19

Countries

United States

Trials that died the same way

• Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
  “Study stopped due to low accrual.” (86% match in meaning)
• Pre-operative Zoledronate in Triple Negative Breast Cancer
  “The study stopped prematurely due to the low accrual rate” (79% match in meaning)
• A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
  “Study closed due to slow accrual and lack of efficacy.” (78% match in meaning)
• Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
  “Study discontinued due to low accrual.” (78% match in meaning)
• Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
  “This study was stopped prematurely due to lack of enrollment within a 1-5-year period.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.